Brief: Insilico Medicine Cayman TopCo, Qilu Pharmaceutical Enter Into Drug Development Collaboration Valued At Over HK$931 Mln
27/01/2026 01:48
Jan 27 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK: INSILICO MEDICINE AND QILU PHARMACEUTICAL ENTER INTO DRUG DEVELOPMENT COLLABORATION VALUED AT OVER HKD931 MILLION COLLABORATION TO LEVERAGE INSILICO'S PHARMA.AI FOR CARDIOMETABOLIC DISEASE MANAGEMENT Further company coverage: 3696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7